Last reviewed · How we verify

Metformin (Background drug) — Competitive Intelligence Brief

Metformin (Background drug) (Metformin (Background drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); Complex I of the mitochondrial electron transport chain Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin (Background drug) (Metformin (Background drug)) — Sanofi. Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Metformin (Background drug) TARGET Metformin (Background drug) Sanofi phase 3 Biguanide AMP-activated protein kinase (AMPK); Complex I of the mitochondrial electron transport chain
metformin or sulfonylurea metformin or sulfonylurea Dr. Milan Gupta marketed Antidiabetic agents (biguanide and sulfonylurea) Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP)
Metformin and insulin Metformin and insulin Takeda marketed Antidiabetic combination (biguanide + insulin) Metformin: AMP-activated protein kinase (AMPK) pathway; Insulin: insulin receptor
medical nutrition therapy + metformin medical nutrition therapy + metformin Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes marketed Combination therapy: dietary intervention + biguanide antidiabetic AMP-activated protein kinase (AMPK) and hepatic glucose metabolism (metformin component)
Metformin discontinue Metformin discontinue University of Texas Southwestern Medical Center marketed Biguanide AMP-activated protein kinase (AMPK); hepatic glucose production
metformin\pioglitazone\exenatide metformin\pioglitazone\exenatide The University of Texas Health Science Center at San Antonio marketed Combination antidiabetic agent (biguanide + thiazolidinedione + GLP-1 receptor agonist) Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide)
metformin/glimepiride combination metformin/glimepiride combination Laboratorios Silanes S.A. de C.V. marketed Biguanide/Sulfonylurea combination AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin (Background drug) — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-background-drug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: